Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
01
09
2018
revised:
13
11
2018
accepted:
13
11
2018
pubmed:
7
12
2018
medline:
7
12
2018
entrez:
4
12
2018
Statut:
ppublish
Résumé
Remodeling of the extracellular matrix (ECM) is a key event in different lung disorders, such as fibrosis and cancer. The most common cell type in the connective tissue is fibroblasts, which transdifferentiate into myofibroblasts upon activation. All myofibroblasts express α-SMA, which has been found to be upregulated in lung fibrosis and cancer. We evaluated the potential of α-SMA as a noninvasive biomarker of activated fibroblasts in lung fibrosis and cancer. A monoclonal antibody was raised against the N-terminal of α-SMA, and a novel competitive enzyme-linked immunosorbent assay (ELISA) measuring α-SMA was developed and technically characterized. Levels of α-SMA were measured in the fibroblast model, "scar-in-a-jar", and in serum from patients with idiopathic pulmonary fibrosis (IPF), chronic obstructive lung disorder (COPD) and non-small cell lung cancer (NSCLC) belonging to two different cohorts. The novel α-SMA assay was developed and validated as technically robust. Based on the scar-in-a-jar results, α-SMA was only present in the fibroblasts activated by TGF-β. In cohort 1, levels of α-SMA were significantly higher in IPF, COPD and NSCLC patients compared to healthy controls (P = 0.04, P = 0.001 and P <0.0001, respectively). The area under the receiver operating characteristics (AUROC) for separation of healthy controls from IPF patients was 0.865, healthy controls from COPD patients was 0.892 and healthy controls from NSCLC patients was 0.983. In cohort 2, levels of α-SMA were also significantly higher in NSCLC patients compared to healthy controls (P = 0) and the AUROC for separating NSCLC and healthy controls was 0.715. In this study we developed and validated a robust competitive ELISA assay targeting the N-terminal of α-SMA. The level of α-SMA was upregulated when adding TGF-β, indicating that α-SMA is increased in activated fibroblasts. The level of α-SMA in circulation was significantly higher in patients with IPF, COPD and NSCLC compared to healthy controls. This assay could potentially be used as a novel noninvasive serological biomarker for lung disorders by providing a surrogate measure of activated fibroblasts.
Identifiants
pubmed: 30504086
pii: S1936-5233(18)30425-X
doi: 10.1016/j.tranon.2018.11.004
pmc: PMC6277250
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
368-374Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Assay Drug Dev Technol. 2013 Mar;11(2):70-92
pubmed: 23046407
J Thorac Oncol. 2014 May;9(5):664-74
pubmed: 24662457
Int J Clin Exp Pathol. 2012;5(1):58-71
pubmed: 22295148
Ann Am Thorac Soc. 2016 Dec;13 Suppl 5:S417-S421
pubmed: 28005427
Br J Pharmacol. 2009 Nov;158(5):1196-209
pubmed: 19785660
Cell Mol Life Sci. 2011 Sep;68(18):3033-46
pubmed: 21637948
Clin Transl Oncol. 2018 Dec;20(12):1582-1591
pubmed: 29796998
Lancet. 2011 Dec 3;378(9807):1949-61
pubmed: 21719092
Biochem Biophys Res Commun. 2012 Jun 22;423(1):158-63
pubmed: 22634307
Am J Pathol. 1996 Feb;148(2):527-37
pubmed: 8579115
Anticancer Res. 2012 Apr;32(4):1463-73
pubmed: 22493387
Dig Liver Dis. 2005 May;37(5):349-56
pubmed: 15843085
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
Eur Respir J. 2007 Nov;30(5):835-9
pubmed: 17978154
J Cell Biol. 2002 May 13;157(4):657-63
pubmed: 11994316
Cancer Med. 2014 Oct;3(5):1136-45
pubmed: 25044252
Clin Cancer Res. 2013 Nov 1;19(21):5879-89
pubmed: 23995859
Hepatol Res. 2012 May;42(5):482-93
pubmed: 22221767
Histol Histopathol. 2011 Jul;26(7):855-66
pubmed: 21630215
Front Pharmacol. 2014 May 27;5:123
pubmed: 24904424
Somatic Cell Genet. 1977 Mar;3(2):231-6
pubmed: 605383